An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ

Breast Cancer Research

Volumn 9, Issue 1, 2007, Pages

  Götte, Martin ^a   Kersting, Christian ^a   Radke, Isabel ^a   Kiesel, Ludwig ^a   Wülfing, Pia ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; SCATTER FACTOR RECEPTOR; SYNDECAN 1; UVOMORULIN; VASCULOTROPIN A; VASCULOTROPIN C; CADHERIN; SDC1 PROTEIN, HUMAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR VASCULARIZATION; CELL CULTURE; FEMALE; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PAGET NIPPLE DISEASE; PATHOLOGY; VASCULARIZATION;

CADHERINS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL PROLIFERATION; FEMALE; HUMANS; LYMPHANGIOGENESIS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-MET; SYNDECAN-1; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 34248212890     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1641     Document Type: Article

References (75)

1. Bernfield M Götte M Park PW Reizes O Fitzgerald ML Lincecum J Zako M Functions of cell surface heparan sulfate proteoglycans Annu Rev Biochem 1999, 68:729-777 10.1146/annurev.biochem.68.1.729 10872465
2. Götte M Joussen AM Klein C Andre P Wagner DD Hinkes MT Kirchhof B Adamis AP Bernfield M Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature Invest Ophthalmol Vis Sci 2002, 43:1135-1141 11923257
3. Götte M Syndecans in inflammation FASEB J 2003, 17:575-591 10.1096/ fj.02-0739rev 12665470
4. Elenius V Götte M Reizes O Elenius K Bernfield M Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1 J Biol Chem 2004, 279:41928-41935 10.1074/ jbc.M404506200 15220342
5. Yip GW Smollich M Götte M Therapeutic value of glycosaminoglycans in cancer Mol Cancer Ther 2006, 5:2139-2148 10.1158/ 1535-7163.MCT-06-0082 16985046
6. Barbareschi M Maisonneuve P Aldovini D Cangi MG Pecciarini L Angelo Mauri F Veronese S Caffo O Lucenti A Palma PD High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis Cancer 2003, 98:474-483 10.1002/cncr.11515 12879463
7. Leivonen M Lundin J Nordling S von Boguslawski K Haglund C Prognostic value of syndecan-1 expression in breast cancer Oncology 2004, 67:11-18 10.1159/000080280 15459490
8. Baba F Swartz K van Buren R Eickhoff J Zhang Y Wolberg W Friedl A Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype Breast Cancer Res Treat 2006, 98:91-98 10.1007/s10549-005-9135-2 16636895
9. Götte M Kersting C Ruggiero M Tio J Tulusan AH Kiesel L Wülfing P Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer Anticancer Res 2006, 26:621-627 16739330
10. Derksen PW Keehnen RM Evers LM van Oers MH Spaargaren M Pals ST Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma Blood 2002, 99:1405-1410 10.1182/blood.V99.4.1405 11830493
11. Peruzzi B Bottaro DP Targeting the c-met signaling pathway in cancer Clin Cancer Res 2006, 12:3657-3660 10.1158/1078-0432.CCR-06-0818 16778093
12. Jiang WG Grimshaw D Martin TA Davies G Parr C Watkins G Lane J Abounader R Laterra J Mansel RE Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET Clin Cancer Res 2003, 9:4274-4281 14519655
13. Bertotti A Comoglio PM Trusolino L Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis Cancer Res 2005, 65:10674-10679 10.1158/0008-5472.CAN-05-2827 16322210
14. Welm AL Kim S Welm BE Bishop JM MET and MYC cooperate in mammary tumorigenesis Proc Natl Acad Sci USA 2005, 102:4324-4329 552784 15738393 10.1073/pnas.0500470102
15. Lee WY Chen HH Chow NH Su WC Lin PW Guo HR Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients Clin Cancer Res 2005, 11:2222-2228 10.1158/ 1078-0432.CCR-04-1761 15788670
16. Beauvais DM Rapraeger AC Syndecans in tumor cell adhesion and signaling Reprod Biol Endocrinol 2004, 2:3 320497 14711376 10.1186/1477-7827-2-3
17. Beauvais DM Burbach BJ Rapraeger AC The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells J Cell Biol 2004, 167:171-181 10.1083/jcb.200404171 15479743
18. Lerwill MF Current practical applications of diagnostic immunohistochemistry in breast pathology Am J Surg Pathol 2004, 28:1076-1091 10.1097/01.pas.0000126780.10029.f0 15252316
19. Acs G Lawton TJ Rebbeck TR LiVolsi VA Zhang PJ Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications Am J Clin Pathol 2001, 115:85-98 10.1309/FDHX-L92R-BATQ-2GE0 11190811
20. Cowin P Rowlands TM Hatsell SJ Cadherins and catenins in breast cancer Curr Opin Cell Biol 2005, 17:499-508 10.1016/j.ceb.2005.08.014 16107313
21. Cavallaro U Liebner S Dejana E Endothelial cadherins and tumor angiogenesis Exp Cell Res 2006, 312:659-667 10.1016/j.yexcr.2005.09.019 16256984
22. Sun D Mcalmon KR Davies JA Bernfield M Hay ED Simultaneous loss of expression of syndecan-1 and E-cadherin in the embryonic palate during epithelial-mesenchymal transformation Int J Dev Biol 1998, 42:733-736 9712528
23. Kato M Saunders S Nguyen H Bernfield M Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells Mol Biol Cell 1995, 6:559-576 301215 7545031
24. Leppä S Vleminckx K Van Roy F Jalkanen M Syndecan-1 expression in mammary epithelial tumor cells is E-cadherin-dependent J Cell Sci 1996, 109:1393-1403 8799827
25. Zimmermann P Tomatis D Rosas M Grootjans J Leenaerts I Degeest G Reekmans G Coomans C David G Characterization of syntenin, a syndecan-binding PDZ protein, as a component of cell adhesion sites and microfilaments Mol Biol Cell 2001, 12:339-350 30947 11179419
26. Alexander CM Reichsman F Hinkes MT Lincecum J Becker KA Cumberledge S Bernfield M Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice Nat Genet 2000, 25:329-332 10.1038/77108 10888884
27. Liu BY Kim YC Leatherberry V Cowin P Alexander CM Mammary gland development requires syndecan-1 to create a beta-catenin/TCF-responsive mammary epithelial subpopulation Oncogene 2003, 22:9243-9253 10.1038/ sj.onc.1207217 14681683
28. Liu BY McDermott SP Khwaja SS Alexander CM The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells Proc Natl Acad Sci USA 2004, 101:4158-4163 384711 15020770 10.1073/pnas.0400699101
29. Wülfing P Kersting C Buerger H Mattsson B Mesters R Gustmann C Hinrichs B Tio J Böcker W Kiesel L Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ Br J Cancer 2005, 92:1720-1728 10.1038/sj.bjc.6602567 15841074
30. Wu Y Hooper AT Zhong Z Witte L Bohlen P Rafii S Hicklin DJ The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma Int J Cancer 2006, 119:1519-1529 10.1002/ijc.21865 16671089
31. De Jong JS van Diest PJ van der Valk P Baak JP Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops J Pathol 1998, 184:44-52 10.1002/ (SICI)1096-9896(199801)184:1<44::AID-PATH984>3.0.CO;2-H 9582526
32. Jiang WG Hiscox SE Parr C Martin TA Matsumoto K Nakamura T Mansel RE Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells Clin Cancer Res 1999, 5:3695-3703 10589789
33. Maeda T Desouky J Friedl A Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis Oncogene 2006, 25:1408-1412 10.1038/sj.onc.1209168 16247452
34. Wülfing P Götte M Sonntag B Kersting C Schmidt H Wülfing C Buerger H Greb R Böcker W Kiesel L Overexpression of Endothelin-A-receptor in breast cancer: Regulation by estradiol and cobalt-chloride induced hypoxia Int J Oncol 2005, 26:951-960 15753989
35. Holland R Peterse JL Millis RR Eusebi V Faverly D van de Vijver MJ Zafrani B Ductal carcinoma in situ: A proposal for a new classification Semin Diagn Pathol 1994, 11:167-180 7831528
36. Wülfing P Kersting C Tio J Fischer RJ Wülfing C Poremba C Diallo R Böcker W Kiesel L Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer Clin Cancer Res 2004, 10:2393-2400 10.1158/1078-0432.CCR-03-0115 15073116
37. Wülfing P Diallo R Müller C Wülfing C Poremba C Heinecke A Rody A Greb RR Böcker W Kiesel L Analysis of cyclooxygenase-2 expression in human breast cancer: High throughput tissue microarray analysis J Cancer Res Clin Oncol 2003, 129:375-382 10.1007/ s00432-003-0459-1 12884024
38. Perneger TV What's wrong with Bonferroni adjustments BMJ 1998, 316:1236-1238 1112991 9553006
39. Lacroix M Leclercq G Relevance of breast cancer cell lines as models for breast tumours: An update Breast Cancer Res Treat 2004, 83:249-289 10.1023/B:BREA.0000014042.54925.cc 14758095
40. Lombaerts M van Wezel T Philippo K Dierssen JW Zimmerman RM Oosting J van Eijk R Eilers PH van de Water B Cornelisse CJ E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines Br J Cancer 2006, 94:661-671 16495925
41. Vos CB Cleton-Jansen AM Berx G de Leeuw WJ ter Haar NT van Roy F Cornelisse CJ Peterse JL van de Vijver MJ E-cadherin inactivation in lobular carcinoma in situ of the breast: An early event in tumorigenesis Br J Cancer 1997, 76:1131-1133 9365159
42. Teo NB Shoker BS Jarvis C Martin L Sloane JP Holcombe C Vascular density and phenotype around ductal carcinoma in situ (DCIS) of the breast Br J Cancer 2002, 86:905-911 10.1038/sj.bjc.6600053 11953822
43. Siitonen SM Kononen JT Helin HJ Rantala IS Holli KA Isola JJ Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer Am J Clin Pathol 1996, 105:394-402 8604681
44. Rakha EA Abd El Rehim D Pinder SE Lewis SA Ellis IO E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance Histopathology 2005, 46:685-693 10.1111/ j.1365-2559.2005.02156.x 15910600
45. Asgeirsson KS Jonasson JG Tryggvadottir L Olafsdottir K Sigurgeirsdottir JR Ingvarsson S Ogmundsdottir HM Altered expression of E-cadherin in breast cancer. patterns, mechanisms and clinical significance Eur J Cancer 2000, 36:1098-1106 10.1016/S0959-8049(00)00062-9 10854942
46. Yoshida R Kimura N Harada Y Ohuchi N The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer Int J Oncol 2001, 18:513-520 11179480
47. Camp RL Rimm EB Rimm DL Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma Cancer 1999, 86:2259-2265 10.1002/ (SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2 10590366
48. Hayashida K Johnston DR Goldberger O Park PW Syndecan-1 expression in epithelial cells is induced by transforming growth factor beta through a PKA-dependent pathway J Biol Chem 2006, 281:24365-24374 10.1074/ jbc.M509320200 16807246
49. Yeaman C Rapraeger AC Post-transcriptional regulation of syndecan-1 expression by cAMP in peritoneal macrophages J Cell Biol 1993, 122:941-950 10.1083/jcb.122.4.941 8394371
50. Parker C Rampaul RS Pinder SE Bell JA Wencyk PM Blamey RW Nicholson RI Robertson JF E-cadherin as a prognostic indicator in primary breast cancer Br J Cancer 2001, 85:1958-1963 10.1054/bjoc.2001.2178 11747340
51. Khoury H Naujokas MA Zuo D Sangwan V Frigault MM Petkiewicz S Dankort DL Muller WJ Park M HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion Mol Biol Cell 2005, 16:550-561 545891 15548598 10.1091/ mbc.E04-07-0567
52. Teo NB Shoker BS Jarvis C Martin L Sloane JP Holcombe C Angiogenesis and invasive recurrence in ductal carcinoma in situ of the breast Eur J Cancer 2003, 39:38-44 10.1016/S0959-8049(02)00248-4 12504656
53. Guidi AJ Schnitt SJ Fischer L Tognazzi K Harris JR Dvorak HF Brown LF Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast Cancer 1997, 80:1945-1953 10.1002/ (SICI)1097-0142(19971115)80:10<1945::AID-CNCR11>3.0.CO;2-Y 9366297
54. Heideman DA Overmeer RM van Beusechem VW Lamers WH Hakvoort TB Snijders PJ Craanen ME Offerhaus GJ Meijer CJ Gerritsen WR Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy Cancer Gene Ther 2005, 12:954-962 10.1038/sj.cgt.7700856 15905856
55. Jeltsch M Kaipainen A Joukov V Meng X Lakso M Rauvala H Swartz M Fukumura D Jain RK Alitalo K Hyperplasia of lymphatic vessels in VEGF-C transgenic mice Science 1997, 276:1423-1425 10.1126/ science.276.5317.1423 9162011
56. Kinoshita J Kitamura K Kabashima A Saeki H Tanaka S Sugimachi K Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer Breast Cancer Res Treat 2001 66 159 164 10.1023/A:1010692132669 11437102
57. Jakobsson L Kreuger J Holmborn K Lundin L Eriksson I Kjellen L Claesson-Welsh L Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis Dev Cell 2006, 10:625-634 10.1016/j.devcel.2006.03.009 16678777
58. Wülfing P Diallo R Kersting C Wülfing C Poremba C Greb RR Böcker W Kiesel L Endothelin-1, endothelin-A- and Endothelin-B-receptor expression in preinvasive and invasive breast disease Oncol Rep 2004, 11:791-796 15010874
59. Pennacchietti S Michieli P Galluzzo M Mazzone M Giordano S Comoglio PM Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell 2003, 3:347-361 10.1016/ S1535-6108(03)00085-0 12726861
60. Haug C Schmid-Kotsas A Zorn U Bachem MG Schuett S Gruenert A Rozdzinski E Hepatocyte growth factor is upregulated by low-density lipoproteins and inhibits endothelin-1 release Am J Physiol Heart Circ Physiol 2000, 279:H2865-H2871 11087242
61. Rosano L Spinella F Di Castro V Nicotra MR Dedhar S de Herreros AG Natali PG Bagnato A Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells Cancer Res 2005, 65:11649-11667 10.1158/0008-5472.CAN-05-2123 16357176
62. Rosano L Spinella F Di Castro V Decandia S Nicotra MR Natali PG Bagnato A Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression Exp Biol Med (Maywood) 2006, 231:1128-1131 16741062
63. Bagnato A Rosano L Spinella F Di Castro V Tecce R Natali PG Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression Cancer Res 2004, 64:1436-1443 10.1158/0008-5472.CAN-03-2344 14973117
64. Jamal S Schneider RJ UV-induction of keratinocyte endothelin-1 downregulates E-cadherin in melanocytes and melanoma cells J Clin Invest 2002, 110:443-452 150409 12189238 10.1172/JCI200213729
65. Bagnato A Natali PG Endothelin receptors as novel targets in tumor therapy J Transl Med 2004, 2:16 436068 15165288 10.1186/1479-5876-2-16
66. Wakeling AE Inhibitors of growth factor signalling Endocr Relat Cancer 2005, 12(Suppl 1):S183-S187 10.1677/erc.1.01014 16113095
67. Ciardiello F Troiani T Caputo F De Laurentiis M Tortora G Palmieri G De Vita F Diadema MR Orditura M Colantuoni G Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer Br J Cancer 2006, 94:1604-1609 16685276
68. Jimenez B Volpert OV Mechanistic insights on the inhibition of tumor angiogenesis J Mol Med 2001, 78:663-672 10.1007/s001090000178 11434719
69. Folkman J Angiogenesis Annu Rev Med 2006, 57:1-18 10.1146/ annurev.med.57.121304.131306 16409133
70. Tolgay Ocal I Dolled-Filhart M D'Aquila TG Camp RL Rimm DL Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors Cancer 2003, 97:1841-1848 10.1002/cncr.11335 12673709
71. Lengyel E Prechtel D Resau JH Gauger K Welk A Lindemann K Salanti G Richter T Knudsen B Vande Woude GF C-met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu Int J Cancer 2005, 113:678-682 10.1002/ijc.20598 15455388
72. Ghoussoub RA Dillon DA D'Aquila T Rimm EB Fearon ER Rimm DL Expression of c-met is a strong independent prognostic factor in breast carcinoma Cancer 1998, 82:1513-1520 10.1002/ (SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7 9554529
73. Nakopoulou L Gakiopoulou H Keramopoulos A Giannopoulou I Athanassiadou P Mavrommatis J Davaris PS c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma Histopathology 2000, 36:313-325 10.1046/j.1365-2559.2000.00847.x 10759945
74. Heimann R Lan F McBride R Hellman S Separating favorable from unfavorable prognostic markers in breast cancer: The role of E-cadherin Cancer Res 2000, 60:298-304 10667580
75. Charpin C Garcia S Bonnier P Martini F Andrac L Choux R Lavaut MN Allasia C Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival Am J Clin Pathol 1998, 109:431-438 9535397